Established supply capacity to enable broad, equitable access towards 3bn doses worldwide

R-Pharm

Doses TBC

SK Bioscience

20mEU Commission

Up to 400m

UK

100m

Fiocruz

100m

Carlos Slim

(Liomont/Mabxience)

150m

CSL

53.8m

Japan

120m

Canada

20m

US

300m

Israel

10m

SBS, SCG

Doses TBC

SII

1 bn

1

Establishing parallel supply

agreements to ensure global

access:

Brazil (Fiocruz)

LatAm (Ex Brazil)

Japan

China

South Korea

Russia with export

to MEA, CIS, Balkans

(R-Pharm)

July

USAMay

UKApril

EuropeAugust

AustraliaSeptember

SII (LMIC)June

CanadaNovember

Israel

CEPI-GAVI COVAX

SE AsiaOctober

Continued engagement with intl. orgs and govts to drive equitable access

CEPI-Gavi / COVAX – 170m

= Countries that have committed to the COVAX Facility as

of December 15

BioKangtai

Up to 200m

New Zealand

7.5m

New ZealandDecember